각막 윤부 줄기세포 결핍증(LSCD, Limbal Stem Cell Deficiency) 시장은 윤부 조직 이식과 같은 조직 기반 기술에 의해 크게 기여하고 있습니다. 2034년까지 새로운 신흥 치료법의 도입은 각막 윤부 줄기세포 결핍증(LSCD) 치료제 시장에 급격한 변화를 가져오는 주요 전환점이 될 것입니다. 조사 대상 국가(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)에 대한 각막 윤부 줄기세포 결핍증(LSCD) 시장 규모는 2020-2034년 조사 기간 중에 22.60%의 CAGR로 고성장을 2034년까지 17억 달러에 달할 것으로 예측됩니다.
각막 윤부 줄기세포 결핍증(LSCD)은 각막 상피 줄기세포/전구세포의 기능 장애로 각막 상피의 정상적인 항상성을 유지할 수 없는 임상 상태를 말합니다.
이러한 세포는 여러 가지 과정에 의해 손상될 수 있으며, 윤부 줄기세포의 손실은 각막 상피 세포를 결막 상피 세포로 대체하여 각막의 정상적인 선명도를 떨어뜨리고 치유 장애, 흉터 및 시력 상실로 이어질 수 있습니다.
상피 불안정성은 질병 과정의 특징으로, 상피가 반복적으로 파괴되고 지속적인 상피 결손이 형성될 수 있습니다. 지속적인 상피 결손이 반복적으로 발생하면 기저 기질에 영향을 미쳐 흉터가 생기거나 해결되지 않는 경우 무균 용융이 발생할 수 있습니다.
세계의 각막 윤부 줄기세포 결핍증(LSCD, Limbal Stem Cell Deficiency) 시장을 조사했으며, 시장 현재 상황/질병 개요 및 치료법/환자 동향/지역별 동향 등을 제공합니다.
The Limbal Stem Cell Deficiency (LSCD) market is hugely contributed by tissue-based techniques like limbal tissue transplantation. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Limbal Stem Cell Deficiency (LSCD) therapeutics market. The sales of the emerging therapies for the treatment Limbal Stem Cell Deficiency (LSCD) in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, adding a value estimated at a total market of $1.7 Billion by 2034.
"Experts believes that the advent of alternative stem cell sources like MSCs and iPSCs heralds a significant shift toward personalized and regenerative therapies in the LSCD market."
Limbal stem cell deficiency (LSCD) describes the clinical condition when there is dysfunction of the corneal epithelial stem/progenitor cells and the inability to sustain the normal homeostasis of the corneal epithelium.
These cells can be damaged by several different processes and the loss of limbal stem cells results in the replacement of corneal epithelial cells with conjunctival epithelial cells, decreasing the normal clarity of the cornea and leading to impaired healing, scarring and vision loss.
Epithelial instability is a hallmark of the disease process, which can lead to repeated breakdown of the epithelium and the formation of persistent epithelial defects. Recurrent episodes of persistent epithelial defects can affect the underlying stroma, leading to scarring or sterile melts in non-resolving cases.
The total prevalent cases of Limbal Stem Cell Deficiency (LSCD) in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). In the United States, the number of individuals living with LSCD is expected to rise to 74,191 by 2034, following a CAGR of 0.8%. As per estimates, the United States will present with the highest prevalence of Limbal Stem Cell Deficiency (LSCD) cases in 2034. Among the EU5, Germany had the highest Limbal Stem Cell Deficiency (LSCD) cases, followed by the UK, France, Italy, and Spain. Japan is reported to have the highest number of treated cases after the United States.
The Limbal Stem Cell Deficiency (LSCD) therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) to USD 1.7 billion. The United States captured the highest market share as compared to the European 5 countries and Japan.
The current standard of care is limited to tissue-based techniques such as limbal tissue transplantation to address LSCD. However, this traditional approach has several disadvantages. Firstly, it requires a substantial amount of healthy limbal tissue, which poses a risk of causing iatrogenic LSCD in the donor eye. Secondly, when the donor limbal tissue is from a living related or cadaveric donor, potent immunosuppression is required to prevent rejection and subsequent failure of the transplanted tissue. This poses challenges for patients, as lifelong immunosuppression can lead to potential risks such as infection or malignancy and may deter some patients from undergoing the procedure.
In the evolving landscape of LSCD management, stem cell-based therapies have emerged as frontrunners, revolutionizing treatment paradigms. Spearheaded by pioneering products like Holoclar, Nepic, Ocural, and Sakracy, these innovative treatments offer new hope to patients suffering from severe ocular surface disorders. Stem cell therapies, by harnessing the regenerative power of limbal epithelial cells, signify a paradigm shift from conventional treatments, offering a sustainable solution to the challenges of LSCD.
In the 2024-2034 forecast period, the market is set to undergo transformative growth with the anticipated entry of new therapies like KPI012 (KALA BIO) and CSB-001 (Claris Biotherapeutics) and others. The emerging therapies will likely replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the LSCD space and more.
Questions Answered
What is the size of clinically and commercially relevant drug-treatable Limbal Stem Cell Deficiency (LSCD) populations, and how will drug-treatment rates change over time?
Potential challenges and opportunities in implementing approved therapy for Limbal Stem Cell Deficiency (LSCD).
What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?
What key drivers and constraints will affect the Limbal Stem Cell Deficiency (LSCD) therapy market over the forecast period?
Report Highlights
Limbal Stem Cell Deficiency (LSCD) - Current Market Trends
Limbal Stem Cell Deficiency (LSCD) - Current & Forecasted Cases across the G7 Countries
Limbal Stem Cell Deficiency (LSCD) - Market Opportunities and Sales Potential for Agents
